Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis

被引:4
|
作者
Ye, Chenyang [1 ]
Wang, Ji [2 ]
Zheng, Shu [1 ]
Chai, Ying [3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent,Sch Med,Canc Ins, Natl Minist Educ,Prov Key Lab Mol Biol Med Sci, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Surg Oncol, Sir Run Run Shaw Hosp, Coll Med, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Dept Thorac Surg, Sch Med, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2016年 / 9卷
关键词
lung cancer; brain metastasis; EGFR; ALK; icotinib; EML4-ALK FUSION GENE; CANCER; CRIZOTINIB; GEFITINIB; MUTATION; REARRANGEMENTS;
D O I
10.2147/OTT.S121923
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We report a rare case of advanced lung cancer with epidermal growth factor receptor and anaplastic lymphoma kinase co-alterations and brain metastasis, in which icotinib treatment was effective for both the primary lung tumor and the brain metastasis. The patient achieved important clinical remission with a progression-free survival for two years. Our treatment strategy appears to be a promising therapeutic approach for this subgroup of patients.
引用
收藏
页码:6605 / 6608
页数:4
相关论文
共 50 条
  • [1] EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report
    Lu, Zhiqin
    Wang, Xia
    Luo, Yuxi
    Wei, Jianping
    Zeng, Zhimin
    Xiong, Qiang
    Cai, Jing
    Liu, Anwen
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 2823 - 2828
  • [2] Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
    Lou, Na-Na
    Zhang, Xu-Chao
    Chen, Hua-Jun
    Zhou, Qing
    Yan, Li-Xu
    Xie, Zhi
    Su, Jian
    Chen, Zhi-Hong
    Tu, Hai-Yan
    Yan, Hong-Hong
    Wang, Zhen
    Xu, Chong-Rui
    Jiang, Ben-Yuan
    Wang, Bin-Chao
    Bai, Xiao-Yan
    Zhong, Wen-Zhao
    Wu, Yi-Long
    Yang, Jin-Ji
    [J]. ONCOTARGET, 2016, 7 (40) : 65185 - 65195
  • [3] Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy
    He, Hengqiu
    Yang, Wendi
    Huang, Yusheng
    Zhang, Xiaoyue
    Peng, Yuan
    Yang, Zhenzhou
    [J]. ANGIOGENESIS, 2022, 25 (01) : 5 - 8
  • [4] Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy
    Hengqiu He
    Wendi Yang
    Yusheng Huang
    Xiaoyue Zhang
    Yuan Peng
    Zhenzhou Yang
    [J]. Angiogenesis, 2022, 25 : 5 - 8
  • [5] Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy
    Hidekazu Oyoshi
    Hidenari Hirata
    Yasuhiro Hirano
    Sadamoto Zenda
    Yuzheng Zhou
    Kento Tomizawa
    Takeshi Fujisawa
    Masaki Nakamura
    Hidehiro Hojo
    Atsushi Motegi
    Shun-Ichiro Kageyama
    Yoshitaka Zenke
    Koichi Goto
    Shunichi Ishihara
    Shinji Naganawa
    Tetsuo Akimoto
    [J]. Clinical & Experimental Metastasis, 2023, 40 : 407 - 413
  • [6] Prognosis after Whole-Brain Radiotherapy for Leptomeningeal Metastasis in Patients with Lung Adenocarcinoma with or without EGFR/ALK Alterations
    Oyoshi, H.
    Hirata, H.
    Hirano, Y.
    Zenda, S.
    Fujisawa, T.
    Nakamura, M.
    Hojo, H.
    Motegi, A.
    Kageyama, S. I.
    Akimoto, T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E60 - E61
  • [7] Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy
    Oyoshi, Hidekazu
    Hirata, Hidenari
    Hirano, Yasuhiro
    Zenda, Sadamoto
    Zhou, Yuzheng
    Tomizawa, Kento
    Fujisawa, Takeshi
    Nakamura, Masaki
    Hojo, Hidehiro
    Motegi, Atsushi
    Kageyama, Shun-Ichiro
    Zenke, Yoshitaka
    Goto, Koichi
    Ishihara, Shunichi
    Naganawa, Shinji
    Akimoto, Tetsuo
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2023, 40 (5) : 407 - 413
  • [8] Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
    Xu, Jian-Ping
    Liu, Xiao-Yan
    Yang, Sheng
    Zhang, Chang-Gong
    Wang, Lin
    Shi, Yuan-Kai
    [J]. THORACIC CANCER, 2016, 7 (04) : 437 - 441
  • [9] An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
    Zhang, Ying
    Tang, Huaping
    Li, Jun
    Li, Meng
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 1351 - 1354
  • [10] The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases
    Eichholz, J.
    Gaeta, B.
    Walch, H.
    Boe, L.
    Kratochvil, L.
    del Balzo, L. A.
    Yamada, Y.
    Yu, Y.
    Zinovoy, M.
    Gomez, D. R.
    Imber, B. S.
    Isbell, J.
    Li, B. T.
    Murciano-Goroff, Y.
    Arbour, K.
    Schultz, N.
    Lebow, E. S.
    Pike, L. R. G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E101 - E102